The Scalpel's Edge

Ep. 33 - GLP-1 Side Effects Patients Are Actually Reporting and What Reddit Data Reveals

Dr. Tim Sayed walks through an April 2026 study published in Nature that analyzed over 410,000 Reddit posts from people using semaglutide and tirzepatide, using AI language models to extract and categorize what patients were actually saying about their experiences on these medications. The study identified roughly 67,000 self-reporting users, and among them, 43.5% described at least one side effect, with nausea leading at 37%, followed by fatigue, vomiting, constipation, and diarrhea. What makes this study notable, and what Sayed spends real time on, is where the real-world data diverges from the clinical trial record. Fatigue appeared far more commonly in Reddit posts than in formal trial reporting. Reproductive symptoms including irregular periods, mid-cycle bleeding, and heavy cycles emerged as a signal in about 4% of users reporting any side effect, something not well captured in current drug labeling. Temperature-related complaints like chills and hot flashes showed up as well, which the study authors connected speculatively to glucagon's known role in thermogenesis. Sayed is careful to carry the study's own caveats: selection bias is real, Reddit skews younger and American, and voluntary self-reporting cannot establish true prevalence. The broader point he lands on is practical. Prescribers should know what patients are reading and talking about, because those conversations are already shaping what people expect and ask about in the clinic. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com [https://info@timsayedmd.com/]Website: timsayedmd.com [https://www.timsayedmd.com/]Instagram: @timsayedmd [https://www.instagram.com/timsayedmd/]YouTube: @Timsayedmd [https://www.youtube.com/channel/UCWmKAMqZIuVzzgkZUAz1cqg/videos]Facebook: Tim Sayed MD [https://www.facebook.com/timsayedmd/]

Ep. 32 - Breast Implant Illness and Explant Surgery: One Patient's Journey Through Symptoms, Revisions, and Recovery

Dr. Tim Sayed speaks with Rachel Blogg, a licensed psychotherapist and athlete who spent roughly three and a half years navigating breast augmentation, multiple revisions, capsular contracture, implant malposition, and eventually explant surgery before finding relief from symptoms she hadn't initially connected to her implants at all. Rachel's account moves through the full arc — from her original decision to augment after breastfeeding two children, to a series of escalating complications including bottoming out, repeated capsular contracture, and an unsanctioned implant exchange that left her significantly asymmetric and heavier, unable to exercise, and experiencing joint pain severe enough that she underwent four separate trigger finger surgeries that, in retrospect, may never have been necessary. Dr. Sayed contextualizes what Rachel experienced — biofilm theory, the mechanics of under-muscle placement and restricted breathing, and why complete capsulectomy matters in explant surgery — while being careful not to overstate what the evidence currently supports about breast implant illness. Rachel describes symptom resolution that began in the recovery room and continued over the following years: finger pain gone, hair regrowing, thyroid levels stabilizing, and twenty-two pounds lost without changing her approach to diet or training. The conversation turns honestly toward the psychological dimension — radical acceptance as a clinical concept, body image work, the role of a supportive partner, and why Rachel, a DBT therapist herself, waited a full year before pursuing her final surgery. The episode doesn't resolve the broader debate around BII, but it doesn't need to. What it offers is one carefully observed account of what recovery from implants can actually look like. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com [https://info@timsayedmd.com/]Website: timsayedmd.com [https://www.timsayedmd.com/]Instagram: @timsayedmd [https://www.instagram.com/timsayedmd/]YouTube: @Timsayedmd [https://www.youtube.com/channel/UCWmKAMqZIuVzzgkZUAz1cqg/videos]Facebook: Tim Sayed MD [https://www.facebook.com/timsayedmd/]

Ep. 31 - Breast Implant Removal and the Flat Chest Decision: What Explant Surgery Really Looks Like

Dr. Tim Sayed opens with a published personal account from a 56-year-old runner and author who had saline implants placed in the early 2000s and chose, two decades later, to have them removed and stay flat. The story moves through familiar territory for explant patients — the original decision made from insecurity, the body changes that followed breastfeeding, the capsular contracture that eventually developed, and the years it took to arrive at a choice that felt genuinely her own. Sayed doesn't frame the original augmentation as a mistake, but he is candid about how often external pressure — cultural, familial, sometimes from a partner — shapes these decisions in ways patients don't fully recognize at the time. He reflects on why pre-surgical counseling matters, and why the question of motivation deserves more attention than it typically gets in a cosmetic surgery context. The conversation also touches on a newly launched device, the Explant Express from Applied Medical Technology, a suction retrieval system designed to help surgeons manage ruptured implants during removal more cleanly. Sayed explains the real surgical challenge it's meant to address — silicone containment when the capsule tears — and notes he hasn't used it yet, but sees a plausible role for it in known rupture cases. What runs underneath both segments is the same honest question: what does it actually mean to accept your body as it is, and how long does that usually take. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com [https://info@timsayedmd.com/]Website: timsayedmd.com [https://www.timsayedmd.com/]Instagram: @timsayedmd [https://www.instagram.com/timsayedmd/]YouTube: @Timsayedmd [https://www.youtube.com/channel/UCWmKAMqZIuVzzgkZUAz1cqg/videos]Facebook: Tim Sayed MD [https://www.facebook.com/timsayedmd/]

Ep. 30 - Oral GLP 1 Is Here - What It Means for Weight Loss

Dr. Tim Sayed takes a closer look at the latest shift in medically supervised weight loss with the FDA approval of an oral GLP-1 medication. After years of injections dominating the space, a once daily pill introduces a new layer of accessibility, convenience, and patient choice. He walks through how these medications actually work in the body, from slowing gastric emptying to quieting food noise, and why they’ve been so impactful for patients struggling with weight loss. The conversation stays grounded in real-world considerations, including affordability, insurance access, and the role compounding pharmacies have played as demand surged. There’s also a thoughtful comparison between competing medications, looking at effectiveness, side effects, and what really matters when deciding between options. Questions around long term use, maintenance, and sustainability are part of the reality, not something to gloss over. It’s not about hype or quick fixes. It’s about understanding what’s changing, what’s promising, and what still requires careful consideration as this space continues to evolve. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com [https://info@timsayedmd.com/]Website: timsayedmd.com [https://www.timsayedmd.com/]Instagram: @timsayedmd [https://www.instagram.com/timsayedmd/]YouTube: @Timsayedmd [https://www.youtube.com/channel/UCWmKAMqZIuVzzgkZUAz1cqg/videos]Facebook: Tim Sayed MD [https://www.facebook.com/timsayedmd/]

Ep. 29 - What a New Oral GLP-1 Study Means for Type 2 Diabetes and Weight Loss

Dr. Tim Sayed takes a thoughtful look at newly published data from the Achieve 3 trial, a 52-week head-to-head study comparing Eli Lilly’s investigational oral GLP-1, orforglipron, to oral semaglutide in adults with type 2 diabetes not adequately controlled on metformin. Published in The Lancet, the study showed greater A1C reduction and more weight loss at higher doses of orforglipron, with improvements appearing as early as four weeks and sustained through the full year. Participants also saw clinically meaningful changes in cardiovascular risk markers, including non-HDL cholesterol, HDL, triglycerides, and systolic blood pressure. Dr. Sayed walks through how the trial was structured, what the numbers actually represent, and what to make of the higher rates of gastrointestinal side effects seen with the more potent dosing. He reflects on what it takes for a medication to move through phase three trials and toward FDA review, and why that rigor matters. From practical issues like dosing and food restrictions to the broader landscape of compounding pharmacies and evolving GLP-1 access, this is a grounded conversation about where the science stands and what may be coming next. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com [https://info@timsayedmd.com/]Website: timsayedmd.com [https://www.timsayedmd.com/]Instagram: @timsayedmd [https://www.instagram.com/timsayedmd/]YouTube: @Timsayedmd [https://www.youtube.com/channel/UCWmKAMqZIuVzzgkZUAz1cqg/videos]Facebook: Tim Sayed MD [https://www.facebook.com/timsayedmd/]